The price of Rigel Pharmaceuticals (NASDAQ: RIGL) closed at $1.55 in the last session, up 3.33% from day before closing price of $1.50. In other words, the price has increased by $+0.0500 from its previous closing price. On the day, 1365939 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at RIGL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 1.97.
Piper Sandler Downgraded its Overweight to Neutral on June 08, 2022, whereas the target price for the stock was revised from $7 to $1.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 05 when RODRIGUEZ RAUL R sold 30,545 shares for $1.14 per share. The transaction valued at 34,821 led to the insider holds 2,036,629 shares of the business.
Santos David A sold 8,918 shares of RIGL for $10,167 on Feb 05. The EVP, Chief Commercial Officer now owns 349,093 shares after completing the transaction at $1.14 per share. On Feb 05, another insider, Schorno Dean L, who serves as the EVP & Chief Financial Officer of the company, sold 7,027 shares for $1.14 each. As a result, the insider received 8,011 and left with 402,891 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RIGL now has a Market Capitalization of 270.27M and an Enterprise Value of 268.72M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.04. Its current Enterprise Value per Revenue stands at 2.03 whereas that against EBITDA is -15.69.
Stock Price History:
Over the past 52 weeks, RIGL has reached a high of $1.96, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is 1.2966, while the 200-Day Moving Average is calculated to be 1.2088.
Shares Statistics:
According to the various share statistics, RIGL traded on average about 930.03K shares per day over the past 3-months and 1.18M shares per day over the past 10 days. A total of 173.40M shares are outstanding, with a floating share count of 170.72M. Insiders hold about 2.09% of the company’s shares, while institutions hold 61.86% stake in the company. Shares short for RIGL as of Feb 15, 2024 were 3.5M with a Short Ratio of 3.77, compared to 3.42M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.01% and a Short% of Float of 2.04%.
Earnings Estimates
The company has 5 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.03 for the current quarter, with a high estimate of -$0.01 and a low estimate of -$0.05, while EPS last year was $0.01. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.01 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.15 and -$0.21 for the fiscal current year, implying an average EPS of -$0.18. EPS for the following year is -$0.09, with 6 analysts recommending between $0 and -$0.18.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $34.1M. It ranges from a high estimate of $43.39M to a low estimate of $28.12M. As of the current estimate, Rigel Pharmaceuticals’s year-ago sales were $51.28M, an estimated decrease of -33.50% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $32.04M, an increase of 22.90% over than the figure of -$33.50% in the same quarter last year. There is a high estimate of $35.1M for the next quarter, whereas the lowest estimate is $30.17M.
A total of 6 analysts have provided revenue estimates for RIGL’s current fiscal year. The highest revenue estimate was $124.48M, while the lowest revenue estimate was $106.33M, resulting in an average revenue estimate of $114.73M. In the same quarter a year ago, actual revenue was $120.24M, down -4.60% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $140.3M in the next fiscal year. The high estimate is $151.8M and the low estimate is $121.04M. The average revenue growth estimate for next year is up 22.30% from the average revenue estimate for this year.
